KM Research Hub
← 返回论文库
无 KM 图 入排:待复核 图源:开放图源暂不可得 入排置信度 0.45

Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer.

Nadeem Riaz, Tyler J Alban, Robert I Haddad, Michelle Saul, Vladimir Makarov, Yingjie Zhu, Ezra E W Cohen, Robert L Ferris, Peter Mu-Hsing Chang, Jin-Ching Lin, Amanda Psyrri, Prerana Bangalore Parthasarathy, Ardijana Novaj, Mruniya Gawali, Douglas Hoen, Phineas Hamilton, Natalie L Silver, Ivan Juric, Daniel Chawla, Ana Gradissimo, Jennifer Ko, Daniel J McGrail, Craig B Davis, Nancy Y Lee, Timothy A Chan

Nat Cancer 7(1) 98-115

PMID41482527
PMCID-
DOI10.1038/s43018-025-01068-0
发表日期2026-01-02
入排依据:The record describes a Phase III randomized trial in oncology with a drug intervention. However, the abstract does not explicitly report any primary or key secondary time-to-event efficacy results (e.g., overall survival, progression-free survival, hazard ratios, Kaplan-Meier curves, or specific outcome data). It focuses on biomarker and resistance mechanism analysis within the trial. Therefore, eligibility cannot be confirmed based on the provided metadata.
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

Immune checkpoint blockade-based multimodal therapy is widely used across oncology; yet drivers of resistance in most cancer types are not well understood. Here, we comprehensively characterized the tumor genome, microenvironment and microbiome in a phase 3 international randomized trial ( NCT02952586 ) to identify factors that shape outcomes to anti-PD-L1 avelumab plus standard-of-care chemoradiotherapy versus placebo/chemoradiotherapy in individuals with locally advanced head and neck cancer. Patients receiving avelumab whose tumors contained distinct immunologic and genetic features had superior outcomes compared to those receiving placebo. By contrast, patients with increased myeloid/neutrophil activities had worse outcomes with avelumab than those treated with placebo. Strikingly, these tumors possessed telltale intratumoral bacteria, elevated tumor-associated neutrophils, high systemic neutrophil-to-lymphocyte ratios and suppressed adaptive immunity. We define tumor ecosystems associated with benefit to chemoimmunotherapy. Our data demonstrate how intratumoral bacteria affect immune checkpoint blockade response within a randomized trial. These discoveries enhance our understanding of combination immunotherapy, provide a useful multiomic resource and identify unanticipated interactions that may guide future therapeutic strategies.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。